Clinical development
Discover our current research program, which highlights our commitment to groundbreaking studies and treatments, based on our expertise in iron metabolism.
Monoferric® (ferric derisomaltose)
In recent years, Pharmacosmos AS has conducted more than 25 clinical trials across a range of disease areas affected by iron deficiency anemia, including chronic kidney disease, inflammatory bowel disease, and a number of other populations.
As part of the continued life-cycle activities for Monoferric® (ferric derisomaltose), Pharmacosmos is committed to studying the impact on additional patient populations. Please refer to www.clinicaltrials.gov for additional information.
As part of the continued development of Monoferric (ferric derisomaltose), Pharmacosmos is currently conducting a phase 3 trial in patients with iron deficiency and symptomatic chronic heart failure to investigate the effect on cardiovascular death and hospitalization for worsening of heart failure. For more details, please refer to: ClinicalTrials.gov (ID NCT06929806).
Cosela® (trilaciclib)
As part of the continued development of Cosela (trilaciclib), Pharmacosmos AS is currently conducting a trial in patients with extensive-stage small cell lung cancer (ES-SCLC) receiving topotecan. For more details, please refer to: ClinicalTrials.gov (ID NCT05874401).
Petadeferitrin
Pharmacosmos AS is currently conducting a phase II trial in patients with transfusion-dependent thalassemia and iron overload. For more details, please refer to: ClinicalTrials.gov (ID NCT05693909).
Petadeferitrin is investigational and has not been approved for commercial use anywhere in the world. Safety and efficacy have not been established.
Pharmacosmos Therapeutics Inc is...
A leader in providing innovative treatments for unmet patient needs, with a focus on iron metabolism and blood related disorders.
